Deep Genomics is a healthcare company that is using artificial intelligence to build a new universe of life-saving genetic therapies.

Deep Genomics develops genetic medicines using our biologically accurate artificial intelligence technology, with a focus on the preclinical development of oligonucleotide therapies 

Deep Genomics was founded in 2014 by Brendan Frey. The company is headquartered in Toronto, Ontario, Canada, with an office in Cambridge, Massachusetts.

Deep Genomics develops an artificial intelligence-powered discovery platform that supports geneticists, molecular biologists, chemists, toxicologists, and drug developers in the identification and development of genetic medicines.

Deep Genomics' AI Workbench enables the company to decode vast amounts of data on RNA biology, identify novel targets for genetically defined diseases, and produce therapeutic programs with a high success rate.

The AI Workbench has made billions of predictions across the entire human genome, for millions of genetic variants, and hundreds of millions of novel compounds.

Deep Genomics is backed by SoftBank Vision Fund 2*, Canadian Pension Plan Investment Board (CPP Investments), Fidelity Management & Research Company, Amplitude Ventures, Khosla Ventures, and others. The company raised $180M in Series C round on Jul 28, 2021. This brings Deep Genomics' total funding to $236.4M to date.